DUBLIN
, Sept. 19, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference on Thursday, Sept. 26, 2024 at 9:20 a.m. EDT (2:20 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc
Alkermes plc
is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-the-td-cowen-4th-annual-novel-mechanisms-in-neuropsychiatry-conference-302253314.html
SOURCE Alkermes plc
